COVID cases close to 30,000 in India; Death toll may cross 1000

COVID cases close to 30,000 in India; Death toll may cross 1000

As the number of COVID-19 cases continues to rise, the total number of positive cases would soon touch the 30,000 mark in India. The death toll which has already reached 934 is also likely to go up in the next 48 hours if the number of recoveries is not significantly improved in states like Maharashtra, Gujarat and Tamil Nadu and other hotspots. While, the health departments, hospitals and other organisations involved in the prevention and treatments are keenly anticipating to achieve a slowdown in the disease transmission soon.

With 1,543 fresh Covid-19 cases reported in the past 24 hours, the total number of cases stands at 29,500 in the country. The death toll went up to 934 after 62 new casualties were reported in the past 24 hours, showed the numbers released by the ministry of health and family welfare.

The total number of cases reported on COVID-19 has crossed 3 million globally with the US having the most number of cases (987,3220), followed by Spain (226,629) and Italy (197,675).

Meanwhile, the human trial for the COVID-19 vaccine developed by Oxford University has begun in the UK on Thursday (23rd April). The new vaccine named ChAdOx1 nCoV-19 will be assessed in healthy volunteers for its safety and ability to generate good immune responses against the SARS CoV-2 virus.

The participants in the study would receive the trial vaccine randomly with half of the participants receiving ChAdOx1 nCoV-19 vaccination while the other half (the control group) gets a commonly used meningitis vaccine MenACWY vaccine.

On the initial day, the first two volunteers randomly allocated as control and test received the vaccines and have been under evaluation for 48hours, based on which the study shall resume.

The university also said that a separate small group of 10 volunteers shall be assigned separately to receive 2 doses of the COVID-19 vaccine four weeks apart.

The vaccine is prepared by combining a genetically modified weakened common cold virus (adenovirus) vector that causes infection in chimpanzees and a spike protein found on SARS-CoV-2 virus can that help the virus gain entry into the cells

Upon immunisation, the vaccine is expected to generate an immune response to the spike protein component of the vaccine that will help the body to recognise and prevent the virus from entering human cells and therefore prevent future infection.

Up to 1102 healthy participants aged 18-55years are expected to be recruited from across the UK for the trial. Various potential vaccines are also waiting to begin trials across the world in the race to combat the pandemic.

Recently, Pfizer Inc. and BioNTech SE also received approval for Germany’s first human clinical trials of a possible coronavirus vaccine.

More than 80 vaccines and several therapeutic drugs are currently under development globally to treat the novel coronavirus are also in clinical trials, the WHO told in a media statement.

Straight Talk